Results 111 to 120 of about 54,693 (255)
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo +16 more
wiley +1 more source
RHINO: An Integrative Multi‐Omics Framework Linking Circadian Physiology to Precision Medicine
RHINO (RHythmic Interacting Network for multi‐Omics) is an integrative framework that maps circadian regulation across diverse genetic and disease contexts and prioritizes druggable circadian targets. Released as an AI‐powered interactive web portal, RHINO unifies genetic, regulatory, disease, and drug–target information, enabling context‐specific ...
Ying Chen +12 more
wiley +1 more source
Evaluation of a New Chemiluminescent Immunoassay-Based Interferon-Gamma Release Assay for Detection of Latent Tuberculosis Infection. [PDF]
Kim KJ, Ryu SE, Lee HN, Oh SH, Chang CL.
europepmc +1 more source
Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten +30 more
wiley +1 more source
Schematic illustration of a biomimetic SKEV@AAV platform targeting p21‐high senescent Kupffer cells (sKCs) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). p21‐high sKCs accumulate in the PVTT microenvironment and establish an immunosuppressive, SASP‐rich environment that facilitates tumor cell proliferation and immune evasion.
Na Ta +10 more
wiley +1 more source
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao +7 more
wiley +1 more source
Clinical Applications of Interferon-gamma Release Assays
Kwang-Sook Woo, Kyeong-Hee Kim
openaire +1 more source
Development of an Interferon-Gamma Release Assay (IGRA) to Aid Diagnosis of Histoplasmosis. [PDF]
Datta K +8 more
europepmc +1 more source
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun +15 more
wiley +1 more source
Is There Value in Performing Yearly Screening for Latent Tuberculosis Infection by Interferon-Gamma Release Assay Among Patients Living With HIV in Non-Endemic Settings? [PDF]
Foppiano Palacios C +6 more
europepmc +1 more source

